FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry

The U.S. Food and Drug Administration (FDA) announced on Tuesday that it will limit regulatory oversight of wearable devices and software designed to support healthy lifestyles, issuing new guidance to clarify its approach toward wellness technology. The move is aimed at encouraging innovation in the rapidly growing digital health and wearable technology market while maintaining basic safety protections for consumers.

Under the updated FDA guidance, low-risk wellness tools such as fitness apps, activity trackers, and smartwatches that promote exercise, healthy habits, or general well-being will continue to be classified as non-medical devices. These products are exempt from strict FDA regulation as long as they do not claim to diagnose, treat, or manage diseases. The agency emphasized that simply providing health-related information, without medical-grade claims, does not trigger regulatory oversight.

FDA Commissioner Marty Makary reinforced this position in a recent interview, highlighting the importance of balancing innovation with patient safety. He noted that artificial intelligence software and tools like symptom-checking apps should be viewed as informational resources rather than replacements for professional medical advice. Makary stressed that discussions prompted by AI-generated health insights should ultimately take place between patients and healthcare providers, either during in-person visits or virtual consultations.

The announcement had an immediate positive impact on the stock market. Shares of continuous glucose monitor manufacturers Abbott, Medtronic, and Dexcom rose between 1% and 4%, while U.S.-listed shares of fitness smartwatch maker Garmin gained nearly 3%. Investors appeared encouraged by the FDA’s clearer stance, which reduces regulatory uncertainty for wearable and digital health companies.

However, the FDA reiterated that boundaries remain. Devices or software that claim to provide medical-grade measurements, such as blood pressure readings, may still face regulation. The agency cited its previous warning to fitness band maker WHOOP, which received a letter last year after introducing a blood pressure insights feature that estimated values used to diagnose hypertension. The FDA has also cautioned consumers about the risks of unauthorized health devices.

Overall, the new FDA guidance signals a supportive environment for wellness technology, promoting innovation while safeguarding public health by preventing misleading medical claims.